From June 29, 2022, to July 2, 2022, we used a self-designed questionnaire to perform a preliminary survey by recruiting web-based volunteers. We conducted The Dynamic Evolution of COVID-19 Vaccination Study, a national, multicenter, observational household tracking survey from China using a stratified random sampling method. Eastern, Central, Western, and Northeast geographical regions within mainland China were selected to form the sample for this study. Therefore, 4 cities were selected from the Eastern (Changzhou and Jiangsu), Central (Zhengzhou, Henan), Western (Xi’ning and Qinghai), and Northeast (Mudanjiang and Heilongjiang) regions.

We calculated the minimum sample size of each region according to the population proportion of China’s Seventh National Population Census. In each province, the sample size of urban and rural areas was determined according to the proportion of population in the Seventh National Population Census, more than 2 cities and 2 rural areas were randomly selected for sampling. For all of the cities and families in the sample, coding was carried out followed by random sampling. Finally, all members of the selected family have been involved in this survey (age≥18 years) and completed the web-based or offline questionnaire with the assistance of the investigators. A total of 2556 households from 4 geographic regions of China were enrolled in the survey.

The study was designed as a 4-stage survey. For the first stage, we conducted the survey from August 3, 2022, to August 14, 2022. Data collection is still ongoing for the second, third, and fourth stages. Here, we describe the results from the first stage of the study only.

Participants were informed of the benefits and risks of participating in this study, and they provided informed consent. All data were used merely for research purposes. This study was approved by the Life Science Ethics Review Committee of Zhengzhou University (2021-01-12-05).

Web-based questionnaires were designed to collect data through a survey conducted through the Wenjuanxing platform. We also conducted a face-to-face interview with participants who cannot use a smartphone. The questionnaire covered five thematic areas: (1) sociodemographic characteristics: age, gender, nation, religion, marital status, educational status, subjective social status in China or community, smoking status, drinking status, and physical activity; (2) health conditions: chronic disease, the history of allergies, self-report health condition (measured by EuroQol 5 Dimensions Questionnaire [28-30]); (3) perception of COVID-19 and its vaccine: public health prevention measures, awareness of COVID-19 vaccines, the channel of accessing information, the way of accessing information, the risk of COVID-19 infection, the history of COVID-19 infection, the convenience of vaccination, and the uptake of COVID-19 vaccine; (4) self-perception (Kaiser-Meyer-Olkin=0.796): perceived severity (Cronbach α=.879), perceived susceptibility (Cronbach α=.865), perceived benefits (Cronbach α=.907), perceived barriers (Cronbach α=.927), and self-efficiency (Cronbach α=.913; Kaiser-Meyer-Olkin=0.886); and (5) trust in medical staff and developers. All questionnaires are shown in Multimedia Appendix 1.

Questionnaires with abnormal answers (contradictions and inconsistencies, eg, inconsistency or contradictions of sex) were excluded. In addition, we also excluded the participants who spent less than 5 minutes completing this questionnaire. Moreover, the remaining questionnaires were carefully reviewed by trained staff, and finally, 6659 questionnaires were deemed eligible for inclusion. The flowchart of participants is shown in Figure 1.

The primary outcome was COVID-19 vaccine hesitancy in both booster and regular booster vaccination, assessed by asking participants “Are you willing to get a booster vaccination of the COVID-19 vaccine?” and “In the future, would you like to get a booster vaccination of the COVID-19 vaccine?” Participants could choose 1 response from the options “(1) willing,” “(2) hesitant or delayed,” “(3) refused,” and “(4) do not interested” from the 2 questions. According to the definition of vaccine hesitancy, option 1 was regarded as “acceptance,” and options 2 and 3 were merged into “hesitancy.” In addition to this, participants were excluded if they selected the option “do not interested” (n=122).

A booster vaccination is a shot that is given after a period of time (which may be 6 months or more) after a population has completed a standard immunization program, and due to the gradual decay of antibodies in the body, the specific immunity in the body needs to be boosted with another booster vaccination. Regular booster vaccinations are administered after a period of booster vaccination to strengthen the immune system.

Chi-square tests were used to test differences in vaccine hesitancy between groups. Binary logistic regression analyses were carried out to examine factors associated with COVID-19 vaccine hesitancy in both booster and regular booster vaccination. A sensitivity analysis was performed by excluding the participants aged ≥80 years to test the robustness of results and assess the source of uncertainty. In stratified multistage sampling, post hoc stratification was used to weight the sample and the corresponding variables so that the sample's estimate of the total was unbiased. Odds ratios, 95% CI, and P values were calculated for each independent variable. All statistical analyses were carried out using SPSS (version 21.0; IBM Corp) and STATA (version 16.0; StataCorp). Differences were regarded as statistically significant if P values were less than .05.

Among the 8002 participants who completed the questionnaire, a total of 1343 participants who did not meet the inclusion criteria were subsequently excluded. Importantly, no statistically significant differences were found between the final 6659 participants included in the analysis and the overall sample of 8002 (P>.05) (Multimedia Appendix 2). The sociodemographic characteristics, awareness of COVID-19 vaccine, trust in the health care system as well as COVID-19 vaccine hesitancy in booster vaccination and regular booster vaccination of all study participants are displayed in Table 1. Overall, 533 adults (8%; 95% CI 7.4%-8.7%) showed a clear COVID-19 vaccine hesitancy in booster vaccination, while 6126 adults (92%; 95% CI 90.3%-94.2%) indicated that they were willing to vaccinate. Meanwhile, 736 participants (11.1%; 95% CI 10.3%-11.8%) expressed their hesitancy about regular booster vaccination of COVID-19 vaccine. Furthermore, we can see clearly that the participants of all ages are evenly distributed, the proportion of female participants (53.2%) is more than male (46.8%), and most of the participants (87.5%) were married.

A higher prevalence of vaccine hesitancy in both booster vaccination and regular booster vaccination was observed among participants with a history of allergies, experiencing chronic disease, lower levels of public health prevention measures or susceptibility or benefits or self-efficiency, higher levels of severity or barriers, and lower trust in both medical staff and vaccine developers (all P<.05; Figure 2).

In the binary logistic regression model, subjective social status in China or community, chronic disease, history of allergies, drinking status, physical activity, public health prevention measures, awareness of COVID-19 vaccines, severity, susceptibility, benefits, barriers, self-efficiency, and trust in medical staff or developers were found to be all independently associated with COVID-19 vaccine hesitancy in both booster vaccination and regular booster vaccination (all P<.05).

After adjusting for potential confounders, we found that unmarried, experiencing chronic disease, history of allergies, low level of physical activity, lower level of public health prevention measures or susceptibility or benefits or self-efficiency, higher level of severity or barriers, and lower trust in medical staff or developers were all positively associated with COVID-19 vaccine hesitancy in booster vaccination (all P<.05). Meanwhile, we observed that participants who were female, with higher educational level, higher level of subjective social status in community, experiencing chronic disease, history of allergies, lower level of public health prevention measures or susceptibility or benefits or self-efficiency, higher level of severity or barriers, lower trust in both medical staff and developers were all positively associated with COVID-19 vaccine hesitancy in regular booster vaccination after adjusting for potential confounders (all P<.05). Detailed results are all shown in Figure 2 and Multimedia Appendix 3.

In particular, participants with higher levels of education and lower levels of trust in medical staff or developers showed stronger COVID-19 vaccine hesitancy and higher rates of hesitancy at the following regular booster vaccination. The same trend could be observed in participants with a history of vaccination allergy and those with chronic disease (Figure 3).

The COVID-19 vaccine hesitancy rate among Chinese residents shows a trend of raising, which was from 8% (533/6659) to 11.1% (736/6659) between the booster vaccination and regular booster vaccination. In addition, some participants’ attitudes toward COVID-19 vaccine booster vaccination were shown to change. There were 5870 and 480 participants who remained vaccinated and hesitant about routine booster vaccination respectively, while there were still 256 participants who would switch from acceptance to hesitancy.

Multimedia Appendix 4 lists 4 attitudinal changes toward COVID-19 booster vaccination, such as acceptance to acceptance, acceptance to hesitancy (ATH), hesitancy to acceptance, and hesitancy to hesitancy (HTH). The results demonstrated that participants who were female, with higher educational level, higher level of barriers, lower level of susceptibility or self-efficiency, and lower trust in developers were positively associated with ATH (all P<.05). Participants with higher levels of physical activity and self-efficiency as well as not experiencing chronic disease expressed their willingness from hesitancy to acceptance (all P<.001). Furthermore, participants who had higher educational level, lower self-report health condition, having from chronic disease, history of allergies, lower level of public health prevention measures or susceptibility or benefits or self-efficiency, higher level of barriers, lower trust in both medical staff and developers were all positively associated with HTH after adjusting for potential confounders (all P<.05). Detailed results are all presented in Figures 4 and 5.

In sensitivity analyses, the exclusion of participants aged >80 years did not significantly alter the outcome of COVID-19 vaccine hesitancy. Effect estimates for the primary outcome remained similar (Multimedia Appendix 5).

This study focused on the hesitancy rate of COVID-19 vaccine booster in the sample from 4 provinces in mainland China, namely Heilongjiang, Jiangsu, Henan, and Qinghai. The vast majority of participants (6126/6659, 92%) indicated a willingness to receive the COVID-19 booster vaccine, with an additional 8% (533/6659) expressing vaccine hesitancy. The higher vaccination rate and lower vaccine hesitancy rate may be attributed to the following reasons: first, China has continued to strengthen postmarketing surveillance of vaccines, emphasizing their safety and efficacy while continuously tracking the incidence of vaccine-preventable diseases and public acceptance of vaccines [26]. Second, the Chinese government has increased the supply of COVID-19 vaccines and set up reasonably designated medical institutions to carry out booster vaccinations, which has improved the accessibility of vaccination services [31]. Finally, the government and communities have used instant communication media such as television, news, and radio to promote the idea that the overall benefits of COVID-19 vaccination outweigh the risks, and disseminated scientific knowledge about vaccination to reduce people’s doubts. At the same time, community staff actively carried out door-to-door campaigns to mobilize residents actively participate in the booster vaccination.

Nevertheless, the hesitancy rate altered dynamically, increasing from 8% (533/6659) to 11% (736/6659) at the next regular COVID-19 booster vaccination. This may be related to the rapid mutation of the COVID-19 virus [10,32] and spot outbreaks in some cities such as Shanghai, Hainan, Zhengzhou, and so forth in mainland China [33]. People are beginning to wonder about the necessity of the COVID-19 booster vaccination and whether it is effective and safe. This result suggests that repeated outbreaks or spot outbreaks are destroying confidence in the COVID-19 vaccine, which will not be conducive to the control of the epidemic. Therefore, it would be relevant to explore the main influences on vaccine hesitancy and its dynamic fluctuations.

Previous studies have indicated that participants with a lower education level expressed a higher level of COVID-19 vaccine hesitancy in a global survey of 17 countries [34], adults in Ontario with less than a bachelor degree were more likely to report unwillingness to COVID-19 vaccination [35], as well as Chinese adults with lower education level endorsed clear vaccine hesitancy response in primary COVID-19 vaccination [26]. However, our findings suggest the opposite view. Those participants with higher levels of education were more reluctant to participate in the regular COVID-19 booster vaccination, showing a clear vaccine hesitancy. Previous studies have demonstrated similar results [36,37]. Likewise, a similar trend was observed in the regular and the booster vaccination attitude conversion (ATH and HTH). The reason for the contrary findings could be attributed to the fact that individuals with a higher level of education may have greater access to information regarding the COVID-19 outbreak and vaccine. This may lead them to believe that the epidemic will come to an end soon and that they will no longer require a booster shot for COVID-19 [5,20]. Alternatively, the highly educated population may have more resources to combat the risk of the COVID-19 epidemic [38,39].

It is worth noting that there was a significant association between experiencing chronic disease, history of previous vaccination allergies, and participants’ hesitancy to receive booster vaccinations. This hesitancy was also found in the conversion of attitudes from booster vaccination to regular booster vaccination. Participants with chronic diseases (hypertension, diabetes, etc) expressed clear hesitancy to receive booster vaccinations and were consistently hesitant to receive regular booster vaccinations. The reason for this consequence may be that people with chronic disease were concerned about whether people with immunodeficiency and immunosuppression should be vaccinated [40,41]. They are confused as to whether having a chronic disease can exacerbate adverse reactions to COVID-19 booster vaccination [42,43]. The same trend can be observed in participants with a history of vaccination allergy. Previous experiences with vaccination allergies have made people wary of the COVID-19 vaccine [44]. They are unsure if they will develop allergic injuries after the COVID-19 booster vaccination [45], so hesitancy about the booster is inevitable. Consequently, widespread education of people would be essential to reduce vaccine hesitancy.

In this study, we found that participants with higher levels of epidemic severity, barriers, and lower levels of susceptibility, benefits, and self-efficacy were more hesitant to receive a booster vaccination. The severity of the epidemic influenced people’s choice, with higher levels of severity instead promoting vaccine hesitancy, which is inconsistent with previous findings [12,46]. This may be due to people being more aware of self-protection, taking more adequate self-protection measures, going out less, or participating in timely nucleic acid testing when the epidemic is severe [47,48]. Although most people have confidence in the vaccine, this attitude does not automatically translate into vaccine use, as there are a variety of other barriers to vaccination [49,50]. While barriers to vaccination (eg, inconvenience and long queues) affect booster vaccination rates, a reasonable number of booster vaccination sites can facilitate vaccination [38], and the current high rate of COVID-19 vaccination in China can be attributed to a large number of vaccination sites. Therefore, in order to increase the booster vaccination rate, it is important to improve the accessibility of vaccination services. Besides, effective measures can be taken simultaneously, including ensuring the supply of vaccines, increasing the number of vaccination staff, improving the vaccination experience, and providing appointment services to reduce the waiting time for vaccination [26,50,51]. Consistent with the results of Włodarczyk and Ziętalewicz [52], higher self-efficacy and the benefits of COVID-19 vaccination influenced people to take part in vaccination, suggesting that we need to expand the perception that the benefits of vaccination outweigh the disadvantages and guide people positively to take part in vaccination with full self-efficacy.

Mistrust of medical staff and vaccine developers is an important factor influencing hesitancy in receiving COVID-19 booster vaccination. This has been demonstrated in previous studies of vaccine hesitancy [53-55]. Low levels of trust in medical staff and developers can lead to hesitancy in receiving COVID-19 booster vaccinations, even regular booster vaccinations. Both experiences of adverse reactions to vaccinations and even the influence of counterfeit vaccines in society have led to suspicion of medical staff and developers [56,57], which directly influences the COVID-19 booster vaccination. Therefore, it is imperative to strengthen the regulation of vaccine development, production, transportation, and vaccination. Strict adherence to industry guidelines and ethical standards will strongly ensure the standardization, safety, and efficacy of vaccines [16,58]. At the same time, it is necessary to strengthen the training of medical staff to enhance the communication between medical staff and residents, which aims to improve the quality of vaccination services. In addition, enhanced screening of patients with contraindications to COVID-19 vaccination is necessary [24,59], and avoiding or delaying vaccination of contraindicated patients will effectively reduce the occurrence and adverse effects of allergic events.

This is the first multicenter nationwide household-based survey to assess the hesitancy of COVID-19 booster vaccination, influencing factors, and its dynamic fluctuation trend with the help of a saturation sample, which is highly innovative and forward-looking. Throughout the survey process, dedicated staff were assigned to follow-up the survey sites in each of the 4 centers, and strict quality control was carried out to ensure that the survey data were complete and authentic. However, there are still several limitations of this study. First, this study is a cross-sectional observational study, the causality association of vaccine hesitancy cannot be established, and it needs to be supported by data from the follow-up surveys. Second, it may introduce reporting bias in the collecting data on COVID-19 booster vaccination. Finally, this survey was conducted on a household-based sample with a population of permanent residents, and the findings may not be applicable to the floating population.

The prevalence of COVID-19 vaccine booster hesitancy is not high in mainland China. However, there is a slight increment in hesitancy on regular booster vaccination. To reduce vaccine hesitancy, targeted information guidance for people with higher education levels and chronic diseases would be fruitful. Furthermore, improving the accessibility of booster vaccination and enhancing people’s trust in medical staff and vaccine developers would be highly effective in reducing vaccine hesitancy.